New drug cocktail aims to outsmart Hard-to-Treat colorectal cancer
NCT ID NCT07079631
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study is testing whether adding two new drugs (BNT314 and BNT327) to standard chemotherapy can help people with metastatic colorectal cancer that hasn't responded well to initial treatment. The trial will enroll about 482 participants across multiple sites. The goal is to see if the combination can shrink tumors or slow cancer growth, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BNT314 (a biologic that helps the immune system fight cancer) combined with BNT327 (an immune checkpoint inhibitor) and chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with metastatic colorectal cancer that hasn't responded well to initial therapy.
What could go wrong
This is an early-phase trial (phase I/II) with a small number of participants, so the benefits are uncertain. Side effects from the combination of drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asklepios Tumorzentrum Hamburg
RECRUITINGHamburg, 22763, Germany
-
Centro Integral Oncologico Clara Campal
RECRUITINGMadrid, 28050, Spain
-
Christie NHS Foundation
RECRUITINGManchester, M20 4BX, United Kingdom
-
Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
-
Guy's & St Thomas' NHS Foundation Trust, Guy's Hospital
RECRUITINGLondon, SE19RT, United Kingdom
-
Hospital HM Nou Delfos
RECRUITINGBarcelona, 08023, Spain
-
Hämatologisch-Onkologische Praxis Eppendorf - HOPE
RECRUITINGHamburg, 20249, Germany
-
National Cancer Center Hospital
RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, 277-8577, Japan
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The Royal Marsden NHS
RECRUITINGSutton, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Vall D'Hebrón Hospital
RECRUITINGBarcelona, 08035, Spain
-
Yale University
RECRUITINGNew Haven, Connecticut, 06511, United States